Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Source: 
Endpoints
snippet: 

AstraZeneca put out word Thursday morning that its lung cancer therapy and EGFR inhibitor Tagrisso met a secondary endpoint of overall survival in a Phase III trial.